Showing 5131-5140 of 7030 results for "".
- European Decentralized Regulatory Procedure Completed for Efinaconazolehttps://practicaldermatology.com/news/european-decentralized-regulatory-procedure-completed-efinaconazole/2468407/Almirall, S.A. announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole, a triazole antifungal compound indicated for the treatment of onychomycosis, under the trade name of Jublia®. The low binding affinity of efinaconazole topical to kerat
- Analysis: HS-Related Genetic Markers Predict Cardiometabolic Outcomeshttps://practicaldermatology.com/news/study-finds-hs-related-genetic-markers-predict-cardiometabolic-outcomes/2468406/A new cohort study suggests individuals with a high polygenic risk score (PRS) for hidradenitis suppurativa (HS) have an increased risk of developing coronary artery disease (CAD) and diabetes. Study researchers used data from 391,481 participants of European ancestry in the UK Biobank, e
- Study Analyzes Metabolites and ADhttps://practicaldermatology.com/news/study-analyzes-metabolites-and-ad/2468384/Bidirectional two-sample Mendelian randomization (MR) analyses in a study published in Scientific Reports indicated that 22 metabolites and one inflammatory protein (S100A12) were significantly associated with atopic dermatitis (AD) pathogenesis. “The levels of amino acid metaboli
- FDA Approves Up To 3 Tubes of Ameluz Topical Gel, 10% In 1 Treatmenthttps://practicaldermatology.com/news/fda-approves-3-tubes-ameluz-topical-gel-10-1-treatment/2468368/The US Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) to increase the maximally approved dosage from one to three tubes of Biofrontera Inc.’s Ameluz® per treatment, the company announced. Biofrontera Inc. said in a press release that the approval
- FDA Approves Otezla for Pediatric Psoriasishttps://practicaldermatology.com/news/fda-approves-otezla-for-pediatric-psoriasis-treatment/2468356/Amgen’s Otezla® (apremilast) has been approved by the U.S. Food and Drug Administration (FDA) for pediatric use in treating moderate to severe plaque psoriasis, making it the first oral option for this condition in children. The approval, which to patients ages 6 and older who weigh at lea
- Triple-Combination Acne Treatment Shows Equal Efficacy Across Sexeshttps://practicaldermatology.com/news/triple-combination-acne-treatment-shows-equal-efficacy-across-sexes/2468352/A post hoc analysis of two phase 3 studies showed clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB) had s
- Study: Excessive Sweating Linked to Sensitive Skinhttps://practicaldermatology.com/news/study-excessive-sweating-linked-sensitive-skin/2468351/A new study indicates a significant connection between primary hyperhidrosis, a condition of excessive sweating, and sensitive skin, where skin overreacts to stimuli like sweat and stress. The study was led by Practical Dermatology Editorial Board member Adam Friedman, MD, FAAD, chair of d
- Tralokinumab Data for H&N AD Presented at EADVhttps://practicaldermatology.com/news/tralokinumab-data-hn-ad-presented-eadv/2468323/Nine-month interim data from the TRACE study, showing that tralokinumab/tralokinumab-ldrm reduced the severity of moderate-to-severe atopic dermatitis (AD) in the head and neck region of the body (H&N), were shared through one of LEO Pharma’s five late-breaking oral presentations at the 33rd
- SEEN Hair Care Closes $9 Million in Series A Fundinghttps://practicaldermatology.com/news/seen-hair-care-closes-9-million-series-funding/2468305/SEEN, the award-winning haircare brand developed by dermatologist Iris Rubin, MD, has closed a $9 million Series A funding. The company said in a press release that this investment will “accelerate SEEN's growth as the premier science-backed, clinically-proven beauty brand, which sits at the inte
- Report: Nonsurgical Aesthetics Revenues Up 9%https://practicaldermatology.com/news/report-nonsurgical-aesthetics-revenues-9/2468303/Data and analytics solutions provider Guidepoint Qsight and investment banking and management consulting firm Skytale Group released a new report on the state of the aesthetics industry, highlighting the continued expansion of the US market. Combined nonsurgical revenues increased by 9% in